MX2022008626A - Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea. - Google Patents

Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.

Info

Publication number
MX2022008626A
MX2022008626A MX2022008626A MX2022008626A MX2022008626A MX 2022008626 A MX2022008626 A MX 2022008626A MX 2022008626 A MX2022008626 A MX 2022008626A MX 2022008626 A MX2022008626 A MX 2022008626A MX 2022008626 A MX2022008626 A MX 2022008626A
Authority
MX
Mexico
Prior art keywords
thyroid hormone
receptor agonists
hormone receptor
substituted triazinones
triazinones
Prior art date
Application number
MX2022008626A
Other languages
English (en)
Inventor
Jiuxiang Zhu
Jingye Zhou
Mingwei Zheng
Original Assignee
Eccogene Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eccogene Shanghai Co Ltd filed Critical Eccogene Shanghai Co Ltd
Publication of MX2022008626A publication Critical patent/MX2022008626A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta solicitud se refiere a un compuesto de la Fórmula (I') o (I): (VER FORMULAS)(I') o (I), o una sal, hidrato, solvato, profármaco, estereoisómero, o tautómero del mismo, el cual modula la actividad de los receptores de la hormona tiroidea, una composición farmacéutica que comprende un compuesto de la Fórmula (I') o (I), y un método para el tratamiento de o prevención de una enfermedad o trastorno regulado por hormona tiroidea.
MX2022008626A 2020-01-13 2021-01-13 Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea. MX2022008626A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020071741 2020-01-13
CN2020107757 2020-08-07
PCT/CN2021/071381 WO2021143706A1 (en) 2020-01-13 2021-01-13 Substituted triazinones as thyroid hormone receptor agonists

Publications (1)

Publication Number Publication Date
MX2022008626A true MX2022008626A (es) 2022-08-22

Family

ID=74418122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008626A MX2022008626A (es) 2020-01-13 2021-01-13 Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.

Country Status (9)

Country Link
US (2) US11780825B2 (es)
EP (1) EP4090652A1 (es)
JP (1) JP2023510835A (es)
KR (1) KR20220128383A (es)
AU (1) AU2021208027A1 (es)
CA (1) CA3164404A1 (es)
IL (1) IL294494A (es)
MX (1) MX2022008626A (es)
WO (1) WO2021143706A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230242492A1 (en) * 2020-06-17 2023-08-03 Autobahn Therapeutics, Inc. Thyromimetics
WO2022099044A1 (en) * 2020-11-06 2022-05-12 Aligos Therapeutics, Inc. 2-pyridones as thyroid hormone receptor modulators
CN114685450A (zh) * 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
CN117624069A (zh) * 2022-08-19 2024-03-01 凯思凯迪（上海）医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DK1088819T3 (da) * 1999-09-30 2005-09-12 Pfizer Prod Inc 6-azauracilderivater som thyroidreceptorligander
DK1262177T3 (da) 2001-05-31 2006-11-20 Pfizer Prod Inc Medicinsk brug af thyromimetiske forbindelser til behandling af hårtab og kompositioner
PT1919878E (pt) 2005-07-21 2010-11-02 Hoffmann La Roche Derivados de piridazinona como agonistas do receptor da hormona da tiróide
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
AU2010240200B2 (en) 2009-04-20 2014-03-13 Mitsubishi Tanabe Pharma Corporation Novel thyroid hormone beta receptor agonist
JP5847533B2 (ja) * 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
CN111801324B (zh) 2018-06-12 2021-10-22 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
JP7445996B2 (ja) * 2019-02-21 2024-03-08 ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド 新規化合物及び甲状腺ホルモン受容体アゴニストとしてのそれらの使用

Also Published As

Publication number Publication date
AU2021208027A1 (en) 2022-07-28
JP2023510835A (ja) 2023-03-15
WO2021143706A1 (en) 2021-07-22
US11780825B2 (en) 2023-10-10
IL294494A (en) 2022-09-01
CN115244037A (zh) 2022-10-25
US20240190846A1 (en) 2024-06-13
US20210230146A1 (en) 2021-07-29
EP4090652A1 (en) 2022-11-23
CA3164404A1 (en) 2021-07-22
KR20220128383A (ko) 2022-09-20

Similar Documents

Publication Publication Date Title
MX2022008626A (es) Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
MX2023000943A (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y metodos de uso de los mismos.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2023006186A (es) Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo.
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
BR0314126A (pt) Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
CR9910A (es) Antagonistas del receptor 3 de la histamina
MX2023008954A (es) Inhibidores de los receptores erbb.
MX2023012971A (es) Agonistas del receptor de orexina y sus usos.
MX2022007105A (es) Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
MX2022013054A (es) Derivados de imidazolidinona y uso medico de los mismos.
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
MX2021012105A (es) Compuestos de pirrol.
MX2024003738A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2023015074A (es) Agonistas de sulfonamidas del receptor de orexina y sus usos.
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
MX2021001804A (es) Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm.
TW200633710A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
MX2023003825A (es) Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados.
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
WO2022099060A3 (en) Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
MX2022011240A (es) Azálidos de urea inmunomoduladores.